Terapie SARS-Cov-2 | Corticosteroidi

In rosso le review, in verde gli RCT.

• The Lancet Respiratory Medicine, editoriale 9 aprile 2021 | “Early treatment with inhaled budesonide to prevent clinical deterioration in patients with COVID-19”
• New England Journal of Medicine, 25 febbraio 2021 | “Dexamethasone in Hospitalized Patients with Covid-19”
• New England Journal of Medicine, 25 febbraio 2021 editoriale | “Research in the Context of a Pandemic”
•  JAMA, 2 settembre 2020 | “Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19The CoDEX Randomized Clinical Trial”
• New England Journal of Medicine, 25 febbraio 2021 editoriale | “Research in the Context of a Pandemic”
• JAMA, 2 settembre 2020 | “Effect of Dexamethasone on Days Alive and Ventilator-Free in Patients With Moderate or Severe Acute Respiratory Distress Syndrome and COVID-19The CoDEX Randomized Clinical Trial”
• JAMA, 2 settembre 2020 | “Association Between Administration of Systemic Corticosteroids and Mortality Among Critically Ill Patients With COVID-19A Meta-analysis”
• JAMA, 30 luglio 2020 | ”COVID-19 and Dexamethasone. A Potential Strategy to Avoid Steroid-Related Strongyloides Hyperinfection”
• Jama, 2 settembre 2020 (editoriale) | “Corticosteroids in COVID-19 ARDSEvidence and Hope During the Pandemic”
• New England Journal of Medicine, 17 luglio 2020 | “Dexamethasone in Hospitalized Patients with Covid-19 – Preliminary Report”
• Science, 16 giugno 2020
  Link: A cheap steroid is the first drug shown to reduce death in COVID-19 patients
• Clinical Infectious Diseases, 19 maggio 2020
  Link: Early Short Course Corticosteroids in Hospitalized Patients with COVID-19